Allogene Therapeutics says favorable result for Servier in Cellectis arbitration

Allogene Therapeutics (ALLO) noted the favorable outcome for Servier in its arbitration with Cellectis (CLLS) as it relates to cemacabtagene ansegedleucel. This decisive win reconfirmed Allogene’s full development and commercial control of cema-cel in the United States, all EU Member States, and the United Kingdom, while clearing the path to obtain full global commercialization rights from Servier. In particular, the tribunal: Rejected Cellectis’s allegations relating to alleged breaches by Servier of its development obligations; Rejected Cellectis’s financial claims, finding that milestone payments tied to the pivotal trial are not due until U.S. FDA acceptance of a Biologics License Application; and Ordered only a partial termination of the license strictly limited to the UCART19 V1 product (formerly known as ALLO-501, which was discontinued in 2021 in favor of ALLO-501A/cema-cel) and directed Cellectis to negotiate in good faith a direct license to Allogene on terms substantially similar to the existing agreement, if Allogene elects to pursue it. With this legal matter resolved, Allogene enters 2026 with improved fundamentals. The company is approaching one of the most meaningful catalyst periods in the allogeneic CAR T field, including a 1H 2026 interim futility analysis comparing MRD conversion with cema-cel following standard fludarabine/cyclophosphamide lymphodepletion versus observation in first line patients with large B-cell lymphoma.